Tuesday, December 12, 2006

Bagolie & Friedman Lecture to Lawyers on Workers' Compensation Practice


New Jersey - December 2006 - Workers' Compensation Trial Lawyers Ricky Bagolie and Alan Friedman were invited to speak to a group of lawyers interested in advanced workers' comp trial tips. The unique program took place on December 2 at Pines Manor in Edison and was sponsored by the Association of Trial Lawyers of America - New Jersey (ATLA-NJ). It featured a panel of some of the most respected workers’ compensation attorneys in the state.

The program was packed with practice pointers that have proven successful in matters ranging from Using Epidemiology to Cross Examining Defense Experts, Post Settlement Enforcement Motions, Navigating the Latest Lien Issues and the Ethical Considerations in Dealing with Problem Clients. "Attendees took home new ideas that they could immediately apply to their current and future cases", said Bagolie.

Ricky Bagolie and Alan Friedman have lectured to attorneys locally, nationally as well as internationally and are the founding members of Bagolie Friedman Injury Lawyers, of Jersey City & Clifton, NJ and affiliate offices in Hollywood, Florida and Brisbane, Australia may be reached toll free at 1-866-333-3529, via e-mail at info@bagoliefriedman.com

Wednesday, December 06, 2006

OSHA Report Of Asbestos in Brake Pads Gets Congressional Scrutiny

Andrew Schneider of the Baltimore Sun reported that OSHA had threatened to suspend an employee for refusing to withdraw an OSHA bulletin describing the hazards of asbestos in brake pads, Asbestos-Automotive Brake and Clutch Repair Work. The article also suggested that former Assistant Secretary of Labor for OSHA, John Henshaw, had inappropriately influenced the agency to rescind the bulletin.

Congressman George Miller (D-CA), soon-to-be chairman of the House Committee on Education and the Workforce sent a letter to Secretary of Labor Elaine Chao saying that he was "alarmed to learn that OSHA was withdrawing and replacing" the bulletin.

Equally disturbing, according to Miller, is the news that DOL proposed to suspend the OSHA employee who drafted the original safety bulletin."

Miller requested all documents relating to communications between OSHA and the Office of Management and Budget, documents relating to Henshaws communications with the Department relating to the bulletin and all documents relating to the development of the bulletin.

Thank goodness that, finally, we have someone in Congress that will be looking out for worker safety.

Saturday, October 28, 2006

Will New Jersey Workers' Comp Benefits Be Extended to Same Sex Couples

"Disparate treatment of committed same-sex couples, moreover, directly
disadvantages their children. We fail to see any legitimate
governmental purpose in disallowing the child of a deceased same-sex
parent survivor benefits under the Workers' Compensation Act or
Criminal Injuries Compensation Act when children of married parents
would be entitled to such benefits."
Mark Lewis and Dennis Winslow, et al. v. Gwendolyn L. Harris, etc., et al. (A-68-05) Complete Decision: http://www.judiciary.state.nj.us/opinions/supreme/a-68-05.pdf

Bagolie Friedman Injury Lawyers are looking to investigate workers' compensation claims involving same sex couples and may be reached toll free at 1-866-333-3529.

Bankruptcy Court Approves Owens Corning's Plan of Reorganization

Toledo, Ohio – September 26, 2006 – Owens Corning (OWENQ.OB) today announced
that Judge Judith Fitzgerald of the United States Bankruptcy Court for the District of Delaware approved the company’s Plan of Reorganization. The Bankruptcy Court’s
approval of the plan paves the way for Owens Corning to emerge from bankruptcy by
the end of October 2006.

“The court’s approval of Owens Corning’s Plan of Reorganization is a significant
accomplishment for our company,” said Dave Brown, president and chief executive
officer. “As a direct result of the hard work of our employees and the continued support of our customers, suppliers and business partners, Owens Corning has the strong business performance and financial resources necessary to make this plan possible. We are pleased to have court approval on a plan that deals fairly and equitably with all our creditors and permanently resolves our asbestos liability.

“Throughout the Chapter 11 process, Owens Corning has remained committed to fairly
compensating individuals who were made sick by exposure to asbestos-containing
products that we produced until 1972,” said Mr. Brown. “This plan allows us to achieve that objective through the funding of a Trust that will allow those affected by asbestos to be compensated in the near future.”

Owens Corning’s creditors and shareholders overwhelmingly supported the plan,
including the asbestos, bondholder, and trade creditor classes, and bank debt holders. Before Owens Corning can emerge from bankruptcy, the plan must also be approved by Judge John P. Fullam of the United States District Court for the Eastern District of Pennsylvania. Following district court approval of the plan, Owens Corning must complete certain administrative steps before it can emerge from Chapter 11.

“We will emerge as a strong company,” said Mr. Brown. “Since 2002, we have
strengthened our financial performance, including increased sales, improved income
from operations and reduced SG&A. These financial achievements are reflected in the
preliminary investment-grade credit ratings that we received from both Standard &
Poor’s and Moody’s, an unprecedented accomplishment for a company emerging from a
bankruptcy restructuring.”

The agreement assumes a total distributable value of $8.627 billion, consisting of the total enterprise value of $5.858 billion, assumed excess cash of $1.432 billion, and Fibreboard trust and asbestos trust assets of $1.491 billion, less existing debt of $55 million and $99 million in assumed value of new shares reserved for employee incentive programs. The full Plan of Reorganization and related Disclosure Statement are available at http://www.ocplan.com.

Owens Corning’s exit financing will come from a combination of new equity, new debt
financing and existing debt at non-debtor Owens Corning entities. The company will
begin distributions to creditors upon the effective date of its emergence from Chapter 11.

About Owens Corning

Owens Corning is a world leader in building materials systems and composite solutions. A Fortune 500 company for more than 50 years, Owens Corning people redefine what is possible each day to deliver high-quality products and services ranging from insulation, roofing, siding and stone, to glass composite materials used in transportation, electronic, telecommunications and other high-performance applications. Since the company’s founding in 1938, Owens Corning has become a market-leading innovator of glass fiber technology with sales of $6.3 billion in 2005 and 20,000 employees in 26 countries. Additional information is available at http://www.owenscorning.com.

On October 5, 2000, Owens Corning and 17 United States subsidiaries filed voluntary petitions for relief under Chapter 11 of the U. S. Bankruptcy Code in the U. S. Bankruptcy Court for the District of Delaware. The Debtors are currently
operating their businesses as debtors-in-possession in accordance with provisions of the Bankruptcy Code. The Chapter 11 cases of the Debtors are being jointly administered under Case No. 00-3837 (JKF). The Chapter 11 cases do not
include other U. S. subsidiaries of Owens Corning or any of its foreign subsidiaries. The Debtors filed for relief under Chapter 11 to address the growing demands on Owens Corning's cash flow resulting from the substantial costs of
asbestos personal injury liability.
...................

Reference
Owens Illinois Bankruptcy Site:
http://www.occlaims.com/

Thursday, October 26, 2006

Excessive Cancer Deaths Found Among IBM Manufacturing Employees

Excessive Cancer Deaths Found Among IBM Manufacturing Employees
Alliance@IBM CWA Local 1701 Calls on IBM to Take Action
Oct 23, 2006 | PRNewswire
A study by Dr. Richard Clapp an epidemiologist at Boston University School of Public health, and published in Environmental Health Journal has raised alarms with IBM employees and retirees. The study, called "Mortality among US employees of a large computer company: 1969-2001," specifically details cancers and mortality rates among IBM employees.

The study confirmed that overall and cancer related mortality is considerably higher among workers engaged in manufacturing computers and component parts when compared with the general population. While this was generally known, this study includes data from the largest database so far IBM's own "Corporate Mortality File." The data comes from 31,941 records about the deaths of people who had worked at IBM's plants for at least 5 years. The study is on the Alliance web site at http://www.allianceibm.org

Earl Mongeon, Alliance@IBM Vice President and a manufacturing worker at the IBM Burlington Vermont site, said: "This study confirms to those of us working in IBM manufacturing processes that the rumors and talk about high levels of cancers and other health problems from working with toxic substances wasn't just idle shop floor talk."


The Alliance@IBM, the advocate group for IBM employees, is calling on IBM and local, state and federal officials to take the following actions in response to this study:

Health surveillance of all who worked at IBM by the company and appropriate Health agencies.
Increase the use of non-toxic substances in all processes and reduce the use of harmful substances.
Employee exposure levels of toxic substances within IBM facilities be reduced significantly.
States and municipalities with computer manufacturing plants to compile cancer maps of areas around the facilities and areas where employees are likely to reside. Results to be made public.
The setting up of a fund to help alleviate the medical costs of affected IBM employees and their families

If you or a loved one developed a cancer that may be related to the job, contact Bagolie Friedman Injury Lawyers now for a confidetial and free consultation.

Wednesday, October 18, 2006

Idaho Teen Sues J&J, Ortho McNeil Over Ortho Evra Birth-Control Patch

Idaho Teen Sues J&J, Ortho McNeil Over Ortho Evra Birth-Control Patch

A new lawsuit was filed in federal court regarding the safety of the popular but controversial birth-control patch Ortho Evra. In the suit, Idaho’s Katy McKellips Braman, who was 17 when she was first prescribed the patch in 2004, claims that Johnson & Johnson and drug company Ortho McNeil failed to sufficiently test the patch before putting it on the market and that they knowingly misled consumers about the risks of the patch when compared to other birth-control alternatives. Braman’s suit is one of hundreds that have been filed throughout the United States.

Braman alleges that she developed deep vein thrombosis, a serious and potentially fatal blood-clot condition, in her left leg because of her use of Ortho Evra. She had been using the drug for little more than a month when she noticed pronounced swelling in the leg, which gradually worsened over the course of days. The condition required hospital treatment and has forced her to take anti-clotting medications on a daily basis. She is suing the companies for damages and all future medical costs related to the condition.


Only last month, the Food and Drug Administration added a warning to the Ortha Evra label, notifying consumers of the increased risks of clotting in legs and lungs for the patch as opposed to the pill. The patch works by releasing estrogen and progestin into the blood. Since it is applied only on a weekly basis, it contains significantly more hormones than more traditional forms of birth control–making the risk of side effects more severe. Last year, there were nearly 9.5 million prescriptions written for Ortho Evra.

In April of this year, the New York Post reported that “women who suffered life-threatening blood clots and strokes on the Ortho Evra birth-control patch have been receiving cash settlements from the manufacturer.” In September, the Post said that “FDA records, obtained by The Post under the Freedom of Information law, show that 17 patch users, ages 17 to 30, suffered fatal heart attacks, blood clots, and possible strokes since August 2002” and added that “scores of other women using the Ortho Evra patch have suffered complications, including 21 ‘life-threatening’ cases of blood clots and other ailments, according to Food and Drug Administration reports obtained by The Post.”

Johnson & Johnson reported in an SEC filing earlier this year that roughly 500 women had filed suit against them over the patch. Earlier today, the company announced profits of more than $2.7 billion in the third quarter alone, on revenues of $13.3 billion. However, hormonal contraceptive sales declined by 4 percent, largely because of the safety issues related to the patch.

Contact Bagolie Friedman Injury Lawyers now for a confidential and free consultation now.

Sunday, October 08, 2006

Jury awards a former railroad employee $1.8 million after he claimed exposure to cleaning solvent at work in Louisville and Corbin caused permane

By James Bruggers
jbruggers@courier-journal.com
According to The Courier-Journal


A Jefferson Circuit Court jury has awarded a former railroad employee $1.8 million after he claimed exposure to cleaning solvent at work in Louisville and Corbin caused permanent brain damage.

Terry L. Williams, 59, of Corbin, had targeted his former employer, CSX Transportation, in the lawsuit. He declined to be interviewed.



CSX spokesman Gary Sease declined to comment. Sease has previously said that the company does not believe solvents sickened workers at CSX or companies that CSX acquired, such as the Louisville & Nashville Railroad.

But the 9-3 verdict in the two-week trial is the latest in a string of litigation in several states involving hundreds of railroad workers.

The Louisville jury awarded Williams $500,000 for medical expenses, $500,000 for loss of income, $500,000 for past mental and physical pain and suffering and $500,000 for future mental and physical pain and suffering, according to court documents filed Tuesday.

Because the jury attributed 10 percent of the negligence to Williams, CSX will be obligated to pay 90 percent of the award, or $1.8 million.

Williams worked for the railroad 34 years, leaving in 2000 after having been diagnosed with toxic encephalopathy. Williams' career as a machinist working on locomotives started at the L&N's old South Louisville shops and ended at a maintenance facility in Corbin.

In 2001 The Courier-Journal found that more than 600 U.S. railroad employees had been diagnosed with brain damage after working years with solvents with little or no protection.

CSX had, as of 2001, paid $35 million in settlements or awards to 466 current or former employees who filed claims under the federal compensation law for railroad employees. Jury verdicts have gone both ways, with railroad companies claiming other factors may have caused illnesses.

Railroads largely phased out use of the chemicals in question by the early 1990s.

Earlier this year, researchers in West Virginia documented that solvents used by railroad workers shrank an area that helps the two sides of the brain communicate.

Contact Bagolie Friedman Injury Lawyers to discuss your potential railroad claim.

Wednesday, September 06, 2006

Workers Comp & Injury Law Blog: Lawsuit Accuses Security Firm of Failing to Pay Overtime

Workers Comp & Injury Law Blog: Lawsuit Accuses Security Firm of Failing to Pay Overtime

Lawsuit Accuses Security Firm of Failing to Pay Overtime

According to Business Wire, Inter-Con, a global security firm, faces a lawsuit for failing to pay current and former employees for required pre-shift overtime work and violating state and federal laws. The class consists of about 2,000 security guards in CA and there is possibility of more throughout other states. The lawsuit seeks an injunction that would require Inter-Con to pay overtime wages and compensation for all current and former employees who were denied overtime pay in CA.

If you feel that you were cheated out of overtime, contact Bagolie Friedman Injury Lawyers now for a confidential and free consultation.

BAGOLIE FRIEDMAN
INJURY LAWYERS

The Five Corners Building
660 Newark Avenue
Jersey City, New Jersey 07306

201-656-8500 phone
201-656-4702 fax

e-mail: ricky@bagoliefriedman.com
e-mail: rickybags@aol.com

Visit our website now at: www.bagoliefriedman.com
Blog with us at: www.bagoliefriedman.com or www.jerseycity.injuryboard.com

Affiliate Offices: Clifton, New Jersey - Hollywood, Florida - Brisbane, Australia

Wednesday, August 30, 2006

Federal Prosecutors Will Appeal Pending Asbestos Case Rulings

Federal Prosecutors Will Appeal Pending Asbestos Case Rulings

A case against W.R. Grace and Co. over an asbestos conspiracy will be appealed by federal prosecutors who disagree with recent court rulings. The prosecutors accuse the company of violating the Clean Air Act and knowingly poisoning former workers and residents. Three rulings however, have undermined their case by dismissing one count of conspiracy and barring the use of "critical evidence" of asbestos samples and scientific research. The Washington Post, Boston Globe 08/25/2006

Beware of Asbestos in Automotive Brake & Clutch Repair Work

Asbestos-Automotive Brake and Clutch Repair Work
SHIB 07-26-2006
"OSHA is issuing this Safety and Health Information Bulletin to inform employees and employers in the automotive brake repair industry of the precautions that must be taken when working with automotive brakes and clutches containing asbestos. In the case of do-it-yourselfers *, OSHA does not have jurisdiction, and OSHA does not require theses practices to be followed. To reduce the potential exposure to asbestos, EPA strongly recommends that all automotive brake and clutch repair work be done by professional auto mechanics. "

If you or a loved one suffers from an asbestos related injury, contact Bagolie Friedman Injury Lawyers for a confidential and free consultation.

Saturday, August 26, 2006

Ortho Evra Lawsuit Filed

A law suit has been filed against Ortho-McNeil Pharmaceutical, Inc., a division of Johnson and Johnson Inc. (NYSE:JNJ), on behalf of a 34 year-old woman. The woman was diagnosed with a severe pulmonary embolism after using the Ortho Evra birth control patch less than two years. The suit was filed in the United States District Court for the District of New Jersey earlier this month.

Saturday, August 12, 2006

Workers Comp & Injury Law Blog: Nationwide Recall of Duragesic Patches Expanded

Workers Comp & Injury Law Blog: Nationwide Recall of Duragesic Patches Expanded

Charite Artificial Disc Recipients Take Legal Steps

Artificial Disc Recipients Take Legal Steps
There are success stories, but more than two dozen patients claim the device is too risky
Aug 4, 2006 | Rong-Gong Lin II | Los Angeles Times
Since the moment a decade ago when Dane Titsworth picked up a box and a disc in his spine burst, he has been in ever-worsening pain.

So it was with great hope that the Bakersfield building maintenance manager agreed last year to a new procedure. It meant replacing the deteriorating disc in his lower back with a Charite-brand artificial one the first artificial replacement disc approved in the U.S.

"The artificial disc was going to restore my full motion and relieve all my pain," he recalled being told by his doctor. "I would be like a new person."

But after the surgery, he said, the pain became excruciating, virtually immobilizing him. He could no longer work, garden, play catch or ride his motorcycle. After about 10 months on sick leave, he lost his job.

"It failed," said Titsworth, 45, a married father of a 13-year-old son and 2-year-old daughter. "It's pretty much stopped my life." And now he is suing the disc's maker, DePuy Spine Inc., a Raynham, Mass.-based subsidiary of Johnson & Johnson.

Used in Europe since the 1980s and approved by the Food and Drug Administration in 2004, the Charite disc is marketed as an alternative to spinal fusion and is part of the growing and sometimes controversial use of spinal surgery.

The disc's maker says the product is safe and has helped thousands of patients. But DePuy had no comment on Titsworth's case or 27 similar lawsuits filed since January. Five involve California plaintiffs.

The suits allege that the disc is "unreasonably dangerous."

"They've designed a defective product that does not work as intended or as advertised, and in fact causes some horrific side effects," said Titsworth's lawyer.

DePuy spokeswoman Debbie Williams says the product garnered high satisfaction rates among patients and surgeons in a two-year, industry-funded study that was filed with the FDA before its approval.

"As with all surgical procedures, there is a potential for adverse events or complications," Williams said in an e-mail. Still, "the clinical evidence shows the Charite artificial disc is an effective treatment and an option for appropriate patients."

She said that the product "preserves some motion" and "has demonstrated a shorter recovery time compared to fusion." Spinal fusion, the leading surgical treatment for damaged discs, involves placing bone grafts around two or more of the vertebrae during surgery. The body then heals the grafts over several months, which "welds" the vertebrae into a rigid section.

Dr. John Regan, a Beverly Hills surgeon who performs surgery using the artificial disc, said fusion might add stress on adjacent, healthier discs, increasing the risk of future damage.

In contrast, an artificial replacement disc is designed to keep the damaged area flexible, said Regan, who receives some royalties from DePuy unrelated to surgeries he has performed.

Some patients say the Charite disc has given them a new chance for an active lifestyle they thought had been lost forever.

Ron Osborn, 57, of Saugus, said he was surprised at how well his Charite disc has performed. The natural disc it replaced had deteriorated so much that the bones on his spine were crushing a major nerve, leaving him unable to walk for weeks at a time.

"Now I'm back," said Osborn, a sales manager for a golf company. "I've got 100% restoration. I have a back of a 20-year-old."

Similarly, Rick Zayed, 38, an aerospace mechanical engineer from Hermosa Beach, went from struggling to lift a laundry basket to swimming, running and mountain biking.

"So far, everything they said it would do, it's been doing," Zayed said.

But Dr. Allyson Fried-Cain, a former foot-and-ankle surgeon who has sued the manufacturer, said that she suffered such an increase in pain after a Charite disc implantation that she lost her practice and had to sell her Marina del Rey home.

"I couldn't do surgery anymore. I couldn't bend over," said Fried-Cain, 52, a former marathon runner whose back injury resulted from a car accident.

"This implant has destroyed my life," she said.

The Charite disc is advertised on its website with the trademarked slogan "natural motion is back," along with a photo of a family walking through a field.

The suits come as spinal surgery is becoming a very lucrative business, with at least $3.2 billion spent last year in the U.S. on spinal fusion.

Millions of Americans who suffer from persistent lower back pain are looking for relief, and employers lose billions of dollars every year from lost work time due to back pain.

Other medical device companies, including West Chester, Pa.-based Synthes Inc. and Minneapolis-based Medtronic Inc., are developing disc replacements.

"It's an enormous commercial opportunity," said Phil Nabone, a medical technology analyst at RBC Capital Markets.

But since its launch, the Charite disc has been controversial.

Although two national insurance carriers and 60 regional providers cover the device, a medical advisory panel for the Blue Cross Blue Shield Assn. said in an evidence-based review last year that there was "no immediately evident advantage" to using the artificial disc.

And this year, the U.S. Centers for Medicare and Medicaid Services questioned the disc's overall effectiveness.

The original two-year trial sent to the FDA showed only that the disc was no worse than a specific type of spinal fusion surgery, the agency said in a 45-page report released in May.

The study is sometimes criticized because it compared the disc with a spinal fusion technique that has fallen out of favor among surgeons.

The trial submitted to the FDA found that 57% of Charite patients achieved "overall clinical success," compared with 47% in the spinal fusion procedure. More than 3 in 5 Charite disc patients who were considered successes continued taking narcotic pain killers two years after the surgery; while 4 in 5 did so in the control group.

But a higher percentage of Charite disc patients suffered severe or life-threatening events than the spinal fusion group: 15% compared with 9%, according to an FDA clinical review.

As a result, the agency ruled that Medicare would bar coverage of the device for anyone older than 60. Local Medicare contractors were allowed to make the decision for anyone younger.

"This composite outcome is unconvincing as a demonstration of health benefit," the Medicare report said.

Some doctors are equally skeptical.

Dr. Sohail Mirza, a University of Washington medical professor, took issue with Charite disc's marketing slogan of "natural motion is back." It "implies that the artificial disc creates a normal spine; it does not," he wrote in the journal Spine last year.

"Contrary to optimistic marketing, the data … argue for caution by patients and surgeons. Hope for a cure of back pain and a marketing bonanza must be held in check," he wrote.

Dr. Charles Rosen, associate clinical professor of spine surgery at UC Irvine, said he has seen 10 patients since late last year, including Titsworth, complaining of worsening pain after they received the Charite disc.

Rosen said he believes the disc is unsafe and should never have been approved by the FDA. After the surgery, some patients suffered fracturing and an abnormal pulling apart of the joints of the spine, he said. Rosen said the two-year study was too short for a disc that will remain in the spine for many years; the average age of a disc recipient is 40.

"There is no solid evidence that this will last for more than five or 10 years and they will not need to have another operation," Rosen said.

Regan, who helped conduct the clinical trial for the Charite disc, said he is convinced the disc is good technology.

"When you focus on the failures, everyone's thinking, 'What's wrong with this?' " Regan said. "Then it spoils it for the many, many patients who are doing great."

If you or a loved one suffer from problems due to a Charite Artificial Disc, contact Bagolie Friedman Injury Lawyers for a confidential and free consultation.

Injured by the Duragesic Fentanyl Patch?

Injured by the Duragesic Patch?
On July 15, 2005 the FDA issued a Public Health Advisory concerning the use of Duragesic Patches (Fentanyl transdermal) in response to reports of deaths in patients using the patch. The FDA is conducting an investigation into the deaths associated with these patches.

The Agency has been examining the circumstances of product use to determine if the reported adverse events may be related to inappropriate use of the patch or factors related to the quality of the product. It is possible that some patients and their health care providers may not be completely aware of the dangers of these potent narcotic drug products and the important recommendations regarding their safe use.

There has been an expanded recall of Duragesic Patches due to possible leaks. Janssen Pharmaceutica, the manufacturer of the Duragesic Patch notified healthcare professionals of an expanded recall of the Duragesic 75 mcg/h, in February 2004. Four additional lots have been subject to the present expanded recall. Some patches from the recalled lots may leak medication due to improper sealing of one of their edges.

If the medication leaks out of the patch, exposure to the medication can result in inadvertent ingestion or increased transdermal absorption of the active opiate component fentanyl, leading to potentially life-threatening complications. In addition, leakage of the medication could lead to inadequate dosing, resulting in treatment failure and/or opiate withdrawal.

The Duragesic Patch is indicated for the management of severe, chronic pain (such as cancer pain) that cannot be managed with less powerful drugs such as acetaminophen-opioid combinations and nonsteroidal analgesics.

Moreover, only patients who are already on and tolerant to opioid therapy, and require continuous opioid administration should use the patch. Approved by the U.S. Food and Drug Administration (FDA) in 1990, the Duragesic patch releases fentanyl, a strong opioid, through the skin at a fixed rate for 72 hours. The patch is available only by prescription.

If you or a loved one used a Duragesic Patch and suffered side effects, please fill out the form at the right for a free lawsuit case evaluation by Bagolie Friedman Injury Lawyers.

Saturday, July 29, 2006

Injured Civilian Contractor Employees Injured in Iraq or Anywhere in the World May Receive Benefits Under the Defense Base Act

If you are injured while working as a civilian for a company supporting the U.S. Department of Defense in Iraq, Kuwait or anywhere overseas, you may be entitled to receive Federal workers' compensation benefits under the Defense Base Act (42 U.S. Code § 1651). One of the benefits, established by the U.S. Congress, is to have attorney representation for free. No attorney’s fees come from a worker’s weekly benefits or settlement. They are awarded to the attorney by the U.S. Department of Labor based on his reasonable time spent on the case.

Established in 1941, the primary goal of the Defense Base Act was to cover workers on military bases outside the United States. The act was amended to include public works contracts with the government for the building of non-military projects such as dams, schools, harbors, and roads abroad. A further amendment added a vast array of enterprises revolving around the national security of the United States and its allies. Today, almost any contract with an agency of the U.S. government, for work outside the U.S., whether military in nature or not, will likely require Defense Base Act coverage.

Claims must be filed in the appropriate district office of the United States Department of Labor. The New York District is located in Manhattan near Bagolie Friedman Injury Lawyers. The New York District covers all claims arising in Iraq, Afghanistan as well as all of Central and South American, Europe and Africa.

All consultations are free and confidential.

Wednesday, July 05, 2006

Researchers Say ″Killer″ Asthma Inhalers Should Be Recalled

Jun 20, 2006 | Consumer Affairs

Researchers from Cornell and Stanford universities have concluded three common asthma inhalers containing the drugs salmeterol or formoterol may be causing four out of five U.S. asthma-related deaths per year and should be taken off the market.

The researchers made their recommendation after concluding a search of medical literature.

They base these conclusions on a statistical analysis of 19 published trials involving 33,826 patients. This so-called meta-analysis found that patients who inhaled the long-acting beta-agonists salmeterol (trade names Serevent and Advair, both made by GlaxoSmithKline) or formoterol (trade name Foradil, made by Novartis Pharmaceuticals) were 3.5 times more likely to die from asthma and 2.5 times more likely to be hospitalized (whether or not death resulted), compared with those taking a placebo.

The reason, say the researchers, is because although these medications relieve asthma symptoms, they also promote bronchial inflammation and sensitivity without warning.

Asthma death is relatively rare, 15 patients in the meta-analysis who were taking the beta-agonists died, compared with three in the placebo group, over a six-month period.

"In total, there are about 5,000 deaths a year due to asthma, whether or not a person is taking a long-acting beta-agonist," said Edwin Salpeter, the J.G. White Distinguished Professor of Physical Sciences Emeritus at Cornell, who led the statistical analysis in the study.

An eminent astrophysicist, Salpeter has more recently focused his attention on medical statistics.

"We can show that overall it is statistically significant that, compared to patients taking a placebo, these long-acting beta-agonists kill a lot of people," he said.

"These asthma deaths are generally in healthy young adults," said his daughter, Shelley Salpeter, the lead author of the paper appearing online and in the June 20 issue of Annals of Internal Medicine. She is a clinical professor of medicine at Stanford's School of Medicine and a physician at Santa Clara Valley Medical Center in San Jose, Calif.

"We estimate that approximately 4,000 out of the 5,000 asthma deaths that occur in the U.S. each year are actually caused by these long-acting beta-agonists, and we urge that these agents be taken off the market," she added.

Adding an anti-inflammatory drug to a long-acting beta-agonist adds little benefit, report the Salpeters.

Advair, for example, (the fourth bestselling drug in the world with $5.6 billion in annual sales), combines salmeterol with an anti-inflammatory drug to provide some protection against bronchial inflammation associated with beta-agonists. But hospitalizations still doubled for patients inhaling a long-acting beta-agonist combined with an anti-inflammatory drug compared with asthma patients taking a placebo and an anti-inflammatory drug by itself.

Of the 19 studies surveyed in the meta-analysis, the largest the Salmeterol Multicenter Asthma Research Trial with 26,000 participants reported a fourfold increased risk for asthma-related deaths and a twofold increase in life-threatening asthma events in patients using salmeterol.

If older people who also suffered from chronic obstructive pulmonary disease were removed from the analysis, the Salpeters report, salmeterol would be associated with a six times greater risk for asthma-related deaths.

The meta-analysis found that 53 of 3,083 patients inhaling beta-agonists were hospitalized for an asthma attack compared with 12 of 2,008 patients who received a placebo, meaning that there was one hospitalization for every 71 patients treated with a long-acting beta-agonist per year.

The Salpeters say that these two long-acting beta-agonists can result in death because tolerance to them develops over time.

"These agents can improve symptoms through bronchodilation at the same time as increasing underlying inflammation and bronchial hyper-responsiveness, thus worsening asthma control without any warning of increased symptoms," said Shelley Salpeter.

"It is particularly frightening that long-acting beta-agonists are detrimental, whether salmeterol or formoterol, whether taken alone or with anti-inflammatory drugs, both for children and for adults," said Ed Salpeter.

Researchers Say ″Killer″ Asthma Inhalers Should Be Recalled

Jun 20, 2006 | Consumer Affairs

Researchers from Cornell and Stanford universities have concluded three common asthma inhalers containing the drugs salmeterol or formoterol may be causing four out of five U.S. asthma-related deaths per year and should be taken off the market.

The researchers made their recommendation after concluding a search of medical literature.

They base these conclusions on a statistical analysis of 19 published trials involving 33,826 patients. This so-called meta-analysis found that patients who inhaled the long-acting beta-agonists salmeterol (trade names Serevent and Advair, both made by GlaxoSmithKline) or formoterol (trade name Foradil, made by Novartis Pharmaceuticals) were 3.5 times more likely to die from asthma and 2.5 times more likely to be hospitalized (whether or not death resulted), compared with those taking a placebo.

The reason, say the researchers, is because although these medications relieve asthma symptoms, they also promote bronchial inflammation and sensitivity without warning.

Asthma death is relatively rare, 15 patients in the meta-analysis who were taking the beta-agonists died, compared with three in the placebo group, over a six-month period.

"In total, there are about 5,000 deaths a year due to asthma, whether or not a person is taking a long-acting beta-agonist," said Edwin Salpeter, the J.G. White Distinguished Professor of Physical Sciences Emeritus at Cornell, who led the statistical analysis in the study.

An eminent astrophysicist, Salpeter has more recently focused his attention on medical statistics.

"We can show that overall it is statistically significant that, compared to patients taking a placebo, these long-acting beta-agonists kill a lot of people," he said.

"These asthma deaths are generally in healthy young adults," said his daughter, Shelley Salpeter, the lead author of the paper appearing online and in the June 20 issue of Annals of Internal Medicine. She is a clinical professor of medicine at Stanford's School of Medicine and a physician at Santa Clara Valley Medical Center in San Jose, Calif.

"We estimate that approximately 4,000 out of the 5,000 asthma deaths that occur in the U.S. each year are actually caused by these long-acting beta-agonists, and we urge that these agents be taken off the market," she added.

Adding an anti-inflammatory drug to a long-acting beta-agonist adds little benefit, report the Salpeters.

Advair, for example, (the fourth bestselling drug in the world with $5.6 billion in annual sales), combines salmeterol with an anti-inflammatory drug to provide some protection against bronchial inflammation associated with beta-agonists. But hospitalizations still doubled for patients inhaling a long-acting beta-agonist combined with an anti-inflammatory drug compared with asthma patients taking a placebo and an anti-inflammatory drug by itself.

Of the 19 studies surveyed in the meta-analysis, the largest the Salmeterol Multicenter Asthma Research Trial with 26,000 participants reported a fourfold increased risk for asthma-related deaths and a twofold increase in life-threatening asthma events in patients using salmeterol.

If older people who also suffered from chronic obstructive pulmonary disease were removed from the analysis, the Salpeters report, salmeterol would be associated with a six times greater risk for asthma-related deaths.

The meta-analysis found that 53 of 3,083 patients inhaling beta-agonists were hospitalized for an asthma attack compared with 12 of 2,008 patients who received a placebo, meaning that there was one hospitalization for every 71 patients treated with a long-acting beta-agonist per year.

The Salpeters say that these two long-acting beta-agonists can result in death because tolerance to them develops over time.

"These agents can improve symptoms through bronchodilation at the same time as increasing underlying inflammation and bronchial hyper-responsiveness, thus worsening asthma control without any warning of increased symptoms," said Shelley Salpeter.

"It is particularly frightening that long-acting beta-agonists are detrimental, whether salmeterol or formoterol, whether taken alone or with anti-inflammatory drugs, both for children and for adults," said Ed Salpeter.

US FDA sets strong warnings for asthma drug labels

US FDA sets strong warnings for asthma drug labels
May 15, 2006 | Reuters
The U.S. Food and Drug Administration said on Monday that product labels for three popular asthma medications have been updated to state that the drugs could increase the chance of severe asthma attacks that could result in death.

The warnings, first proposed last November, involve long-acting bronchodilator medicines Advair and Serevent, made by GlaxoSmithKline Plc, and Foradil from Novartis AG.

In a public health advisory issued on its Web site, the FDA said the inhaled drugs should only be used after other medicines, such as inhlaed corticosteroids, fail to control asthma.

Thursday, June 29, 2006

Bay Area asbestos removers settle suit

Bay Area asbestos removers settle suit
Jun 29, 2006 | AP
An asbestos removal contractor and a property management company agreed to pay air-quality regulators $430,000 to settle claims they improperly removed asbestos from San Francisco Bay Area buildings.

The fines were the largest asbestos reporting and removal penalties the Bay Area Air Quality Management District has levied, the agency said Tuesday.

USA Properties Fund Inc. and USA Multifamily Management Inc. agreed to pay $300,000 on allegations it used unqualified workers to remove asbestos from the ceiling of a Concord apartment complex.

Two companies fined $430,000 for asbestos violations

Associated Press
OAKLAND, Calif. - An asbestos removal contractor and a property management company agreed to pay air quality regulators $430,000 to settle claims they improperly removed asbestos from San Francisco Bay area buildings.

The fines were the largest asbestos reporting and removal penalties the Bay Area Air Quality Management District has levied, the agency said Tuesday.

A Roseville property management company, operating as USA Properties Fund Inc. and USA Multifamily Management Inc., agreed to pay $300,000 on allegations it used unqualified workers to remove asbestos from the ceiling of a Concord apartment complex.

The workers failed to protect themselves and apartment residents from exposure, according to a lawsuit filed in Contra Costa County Superior Court in March.

In the second case, a Hayward asbestos abatement contractor, operating as Synergy Environmental Inc. and Synergy Enterprises Inc., agreed to pay $130,000 in penalties for allegedly failing to properly notify regulators of more than 250 removal jobs it performed in 2002 and 2003.

Calls to both companies were not immediately returned Wednesday.

Inhaling asbestos fibers can cause lung cancer and other serious diseases.

Wednesday, June 07, 2006

Worker Dies in Industrial Leak Near Pensacola


Worker Dies in Industrial Leak Near Pensacola
Jun 7, 2006 | www.wsfa.com
Investigators are working to determine the cause of a toxic gas leak at an industrial plant near Pensacola that killed one worker.

Authorities say the victim died after inhaling toxic hydrogen sulfide gas at the Blackjack Creek Treating Facility in Allentown, about 20 miles northeast of Pensacola. The toxic chemical is created in the process of making crude oil. Joseph Smith was injured, but has been treated and released from the hospital.

Fire officials say Monday's leak did not affect anything outside the plant or its boundaries. The plant was closed by the Florida Department of Environmental Protection in 2002 while extensive repairs were made to reduce sulfur dioxide and possible hydrogen sulfide emissions.

The company paid $125,000 in civil penalties and completed a pollution prevention project instead of the balance of the penalties, according to a consent order

Tuesday, June 06, 2006

First trial in nationally consolidated welding cases starts

First trial in nationally consolidated welding cases starts
Jun 4, 2006 | M.R. KROPKO | AP
Ernesto G. Solis often welded as part of his maintenance work at a naval air station in Corpus Christi, Texas.

Solis, 57, married and the father of four adult children, still works, but avoids welding. He believes that years of exposure to welding fumes has taken a serious toll on his health. His lawyers say his physical skills have gradually deteriorated.

Solis has become the focus of a federal court trial here that may help set a national legal precedent for thousands of other cases in which workers allege manganese exposure from welding has led to Parkinson's disease.

Solis' case would be the first welding fume case to go to trial among the thousands that were consolidated in U.S. District Court in Cleveland in 2003. Judge Kathleen M. O'Malley asked lawyers to be ready with opening statements Monday, and the trial could last about three weeks.

Defendants in the case are Lincoln Electric Holdings Inc., Hobart Bros. Co., TDY Industries Inc. and the ESAB Group.

"We don't believe that welding is responsible for Mr. Solis' alleged ailments," said Brandy Bergman, a spokeswoman in New York for lawyers representing welding industry defendants. "We are confident that this Cleveland jury will join the overwhelming majority of other juries around the country that have already heard and rejected similar claims."

Other welding fume cases were tried in state courts and in federal courts before the 2003 consolidation. There are about 40 percent fewer such cases pending than there were a year ago, Bergman said.

Solis' lawsuit began four years ago in Texas and contends that from 1973 to 2001 he was exposed to toxic manganese fumes from welding. The lawsuit alleges that manganese in more than trace amounts can damage the human nervous system and limit a person's ability to think, talk and move.

To coordinate the pretrial process of thousands of similar cases, they were consolidated in O'Malley's court in Cleveland, a process known as an MDL, or multidistrict litigation. There are at least 3,800 consolidated cases pending. Some of those may end up in other courts, after the first few are tried to give attorneys guidance on which arguments will succeed and which won't.

Drew Ranier, one of a team of lawyers representing Solis, said Friday before jury selection began that welding fumes are an ongoing public health concern among workers in construction and manufacturing.

"The overall picture is that there are thousands of welders being exposed to welding fumes, and there will be more cases until this is stopped," Ranier said.

The Solis lawsuit asks a jury to determine an appropriate award of damages, but does not specify an amount.

In September, another case nearly became the first to go to trial before O'Malley, but was settled for at least $1 million shortly before jury selection.

Charles Ruth, of Lucedale, Miss., had been a welder at Ingalls Shipyard, in Pascagoula, Miss., and began having various physical problems. His lawyers said he suffered shakes, balance and speech problems.

Because of the settlement, a jury did not decide whether welding fumes could be linked to Ruth's problems

Tuesday, May 30, 2006

Abused children may get more time to sue

Bill would increase statute of limitations to six years from two

May 30, 2006 | BETH MILLER | The News Journal
Victims of child sexual abuse by an adult would have more time to sue for damages under a bill expected to reach the General Assembly today.

The bill, sponsored by Rep. Greg Lavelle, R-Sharpley, and Sen. Karen Peterson, D-Stanton, would extend the time from two years to six years after the abuse occurs or to six years after the abuse is discovered to be the cause of a victim's emotional or physical damage.

The bill also would give new life to claims of abuse that have been barred by Delaware's civil statute of limitations, granting a two-year window in which such claims could be filed.
Advertisement

"That would be awesome," said Valerie Marek, executive director of Survivors of Abuse in Recovery, which supports the recovery of many abuse victims. "A lot of kids are threatened into keeping their mouths closed. By the time they are strong enough to confront it, it's years later and major damage has been done."

California passed a similar law, some states revised their statute of limitations, and other states are debating the issue, which gained prominence after the scandal of child sexual abuse by priests emerged nationally in 2002.

Navy Lt. Cmdr. Kenneth Whitwell urged Delaware lawmakers to change the state's statute of limitations last fall, when he filed suit claiming he was sexually abused by a priest who taught at Archmere Academy in the mid-1980s. Some of the abuse occurred during ski trips to Vermont, Whitwell said.

Delaware's statute of limitations would have barred Whitwell's suit, so it was filed in federal court to leverage the Vermont statute of limitations, which is six years past the time of the abuse or six years after the damage caused by the abuse is recognized.

"A civil window is the single most effective step we have toward preventing future abuse," Whitwell said Friday. "It exposes the predators now and it exposes people who enable the abuse, who protect those people, who shield molesters, who destroy documents. We know there are people out there who don't want this to get out into the open."

The legislation is meant to address abuse by individuals and the institutions that employ them. It does not target the Catholic Church or any other group, said Lavelle, who is Catholic.

"It's much broader than that," he said. "This impacts anyone whose charge it is to be responsible and watch over children; Boy Scouts, Girl Scouts, the YMCA, day cares, private schools."

Split support

Tony Flynn, lawyer for the Catholic Diocese of Wilmington, which includes parishes throughout Delaware and the Eastern Shore of Maryland, said the diocese generally supports changing the civil statute.

"We think whatever clock runs against a victim of sexual abuse should not begin to run until they are an adult," Flynn said. "If you create a period of time long enough, you can deal with the valid concern that victims of sexual abuse as minors have difficulty coming to grips with the abuse and its effects."

But, he said, the diocese sees problems in the "discovery approach," in which the time limit does not begin until the victim remembers the abuse or realizes that emotional or physical difficulties were the result of the abuse. And it would "vigorously oppose" any effort to revive claims already barred by the statute of limitations.

"There are a number of ways to deal with this, so I'm not drawing a line in the sand for this particular solution," Lavelle said. "I view this as the beginning of a public discussion."

Extending the two-year civil limit has broad support, Lavelle said. Addressing old claims with a retroactive bill is likely to face tougher debate.

Retroactive problems

Delaware lawmakers removed the statute of limitations for criminal prosecution of child sexual abuse a few years ago, including a window of opportunity during which older cases could be revived and prosecuted. But shortly after that bill was signed into law, the U.S. Supreme Court ruled on a similar case, striking down the retroactive window as unconstitutional.

"But the average age of an abused child is 9 years old," Peterson said. "What child is going to hire an attorney and file suit before he or she is 11? And with a lot of older cases people from my generation didn't talk about it. If you did, you got spanked and sent to your room. It was a whole different mentality in those days. You didn't cause problems in the family."

Reviving old cases raises many problems, Flynn said.

"Somebody abused 50 years ago could file suit," he said. "The evidence is lost, the witnesses are lost, dead or unavailable, documents are difficult to find in my view that is a denial of due process. Once a claim is barred by operation of a statute, a defendant has the right to rely on that and clear the books of the claim. Insurance programs and risk management are all predicated on what the statutes of limitation are. If you buy insurance and the rules change, you're stuck."

Ed Burke, a member of St. John's-Holy Angels parish near Newark who was abused by a priest as a boy in Iowa, said the law would give children justice and additional protection. He works with the northern Delaware chapter of Voice of the Faithful, formed to support survivors of priest abuse.

"My hope is that the state legislators will take the high ground and force the spiritual leaders to offer some form of justice to the abused, who in many cases have suffered from years of neglect," he said.

Flynn doubts legislators have enough time to devote to such a significant issue before their June 30 deadline.

"There are only 16 legislative days left in June," he said. "I doubt they can have the kind of discussion and analysis that's required for a bill of such sweeping scope. It's something that deserves more reflective consideration."

And, Flynn said, the bill still doesn't address another arena of abuse.

"If the aim of the bill is to prevent abuse, which is a major priority of the church, we're leaving untouched in this legislation a place where abuse occurs the public school system," he said. "It is immune from these suits."

Saturday, May 20, 2006

Jersey City Lawyer Wins $16.4 million Jury Award for Asbestos Victims in Brooklyn


Jersey City, NJ - May 5, 2006 A Brooklyn jury awarded three retired Long Island Railroad (LIRR) workers a total of 16.4 million dollars for lung disease caused by their exposure to asbestos while working for the railroad. Following an eight day jury trial before the Honorable Lawrence Knipel, Albito Velez-Zapata of Massepequa Park, New York was awarded 8 million dollars, Lincoln Aguirre of Deer Park, New York was awarded 6 million dollars and James Harrington of Brookville, New York was awarded 2.4 million dollars. The consolidated claims were filed under the Federal Employee's Liability Act (FELA), a special law designed to protect interstate railroad workers.

The workers, represented by Alan T. Friedman of Jersey City's Bagolie Friedman Injury Lawyers and Paul Garner, affiliated with Jersey City's Horn Shechtman, were exposed to deadly asbestos fibers while grinding gaskets on a high revolution wire wheel and while working around contaminated rail cars and locomotives. The jury found that the railroad knew about the dangers of asbestos dust beginning in the 1930s and failed warn their workers of the dangers and failed to protect them from the deadly fibers.

LIRR argued that the dust masks were available to the workers, despite the fact that their own Asbestos Awareness Program advised that dust masks were not adequate protection for workers exposed to asbestos. This Asbestos Awareness Program was not implemented until the 1990's, long after other industries had reacted to their asbestos problems. Additionally, the Long Island Railroad was fined by the State of New York in the 1990's for failing to implement a Right to Know program to advise their workers of workplace hazards. A Federal law requiring this type of program had been passed in the 1980's.

"The LIRR treated these workers as if they were expendable or disposable, just like the machines that it was their job to repair. The railroad considered them human overhead. This jury told the LIRR in a loud, clear voice that this is no way to treat your employees"
said attorney Alan Friedman.

Alan T. Friedman has been certified as a Civil Trial Attorney by the New Jersey Supreme Court and is a founding partner of Bagolie Friedman Injury Lawyers, with offices in Jersey City and Clifton, New Jersey, Hollywood, Florida and an international affiliation in Brisbane, Australia. He can be reached toll free at 1-866-333-3529, via e-mail at alan@bagoliefriedman.com, or on his website at www.bagoliefriedman.com.

My New Blog

I must be a glutton for punishment but, alas, I have a new blog. It is the Jersey City Personal Injury Lawyer Blog and it can be found at http://jerseycity.injuryboard.com. The most recent posting is on Truck and Tractor Trailer accidents. Check it out.

Friday, May 19, 2006

Formaldehyde fears in FEMA trailers

By Sean Gardiner
South Florida Sun-Sentinel
Posted May 18 2006


Using air-monitoring badges supplied by a Boca Raton company, a national environmental organization found high levels of formaldehyde in trailers supplied by FEMA for those stranded after hurricanes in Mississippi and Louisiana.

The Sierra Club announced Wednesday that only two of the 31 FEMA trailers tested in those states were below the formaldehyde air safety limit recommended by the federal Environmental Protection Agency and the American Lung Association, said Chris Smith of the Sierra Club.

Smith said he expects further formaldehyde tests will be conducted on FEMA-issued trailers in Mississippi and New Orleans but wasn't sure if any testing will be done in Florida.

Currently there are more than 1,500 FEMA trailers and mobile homes housing Florida hurricane refugees, according to FEMA statistics.

In a news release issued on Wednesday about the testing, the Sierra Club stated that formaldehyde -- a colorless, strong smelling gas that is a carcinogen -- usually comes from pressed particleboard or glue.

Thursday, May 18, 2006

Humira or Remicade May Triple Risk of Cancer

Humira or Remicade May Triple Risk of Cancer

CHICAGO, Illinois (AP) — Rheumatoid arthritis patients taking Humira or Remicade face triple the risk of developing several kinds of cancer and double the risk of getting serious infections, a study led by the Mayo Clinic found.The analysis builds on previous reports about the risks associated with Abbott Laboratories’ Humira and Centocor’s Remicade. But the earlier research focused mostly on one kind of cancer — lymphoma — and infections such as tuberculosis and pneumonia.

The new study found an apparent link to other cancers, too, including skin, gastrointestinal, breast and lung tumors. It also quantifies the risks and says high doses appear to be the riskiest.

While the drugs’ packaging information mentions some of the risks, the manufacturers said the new study does not prove that the medication is at fault, and they said the research was flawed.

To read full story, click here.

Contact Bagolie Friedman Injury Lawyers for a confidential and free consultation.

Friday, May 12, 2006

Birth-control patch linked to blood clots, strokes

Dozens of womanm have sued Ortho Evra manufacturer Ortho-McNeil Pharmaceutical Inc. and its parent company, Johnson & Johnson, arguing that the country's only birth-control patch causes debilitating blood clots, strokes and even death. The patch is still on the market.

In U.S. District Court in Newark, N.J., where 37 cases have been filed, the stories are similar: An otherwise healthy Georgia woman develops a pulmonary embolism; a Maine woman suffers from a blood clot in her right lung; a 12-year-old girl in Indiana is diagnosed with deep-vein thrombosis.

Julie Keenan, spokeswoman for Ortho-McNeil, declined to comment on the allegations because of the ongoing litigation.

For many of the women, the long-term effects have been devastating. Some will be on blood thinners for the rest of their lives.

The lawsuits contend that Ortho-McNeil rushed the patch onto the market without adequate testing. The company may have been nervous that it would lose money when its patent for the birth-control pill Ortho Tri-Cyclen ran out, the suits say, and pushed to get the patch on pharmacy shelves to offset any red ink.

Lawyers handling the cases, which have been filed in federal courts across the country as well as in Superior Court in Hudson and Middlesex counties, say they are more clear-cut than other recent pharmaceutical litigation, such as the Vioxx lawsuits.

"You're dealing with primarily women ages 18 to 35 who don't have a lot of pre-existing conditions to begin with," said, a Hackensack lawyer who is working with a South Carolina law firm on a dozen cases. "The reason why people are getting the blood clots is a lot cleaner."

At a hearing last week in U.S. District Court in Ohio, where the federal cases have been consolidated, a Johnson & Johnson lawyer announced the company hopes to settle the lawsuits. Already, 11 women who filed suit in Hudson County have received settlements, although the amounts are sealed.

Generally lawsuit settlements are viewed as positive outcomes for plaintiffs, but they can be a mixed blessing in drug cases.

Saturday, May 06, 2006

Respironics PLV Continuum Ventilator: Class 1 recall due to air flow valve breakage and failure to ventilate

Respironics and FDA notified healthcare professionals about the Class 1
recall of this device, a mechanical ventilator used to control or assist
breathing. The ventilator is intended for home, institutional and
portable settings and may be used for invasive as well as noninvasive
ventilation. A design flaw can cause lead wires in the air flow valve to
break during use. When this happens the ventilator stops providing
mechanical ventilation. Customers should safely transition patients in
their care from the PLV Continuum Ventilator onto other comparable
patient support devices. If customers do not have a suitable ventilator
to use for their patients, they should contact Respironics at
760-918-7328 to make suitable substitute arrangements.

If you or a loved one has been injured by this device, contact Bagolie Friedman
Lawyers now for a confidential and free consultation.

Read the complete MedWatch 2006 Safety summary including a link to the
recall notice, by clicking here.

Tuesday, April 18, 2006

NYC Wrong on WTC Rescue and Recovery Worker Injuries

From Newsinferno

Date Published: Sunday, April 16th, 2006
By Steven DiJoseph

When it comes to human tragedies, there is always a big difference between what people know and what they will admit to. The facts determine the former while money, as in all other aspects of life, often determines the latter.

Consider the following examples of this rather insincere view of reality:


Everyone knew safer cars could be designed and built but, for decades, the auto industry was able to delay the implementation of such things as seat belts, air bags, and emission systems because of the added expense involved. In the meantime, hundreds of thousands of people died needlessly.
Cigarettes kill people, period. No secret there, right? Yet for decades, big tobacco hid and denied that fact while it continued to market its products without warnings and in a way that enticed people to smoke rather than to avoid it at all costs. Unnecessary death toll? Millions, at the very least – and continuing.
Agent Orange, the defoliant, that the U.S. saturated Viet Nam with from the air up until 1971, was loaded with powerful chemical agents that really had no business being dropped on civilians and military personnel. The dioxins Agent Orange (as well as Agents Purple, Pink, Blue, and Green) contained are carcinogens as well as teratogens. Once responsible scientists and doctors began linking cancers and other serious diseases in thousands of servicemen and their offspring directly to their exposure to those chemicals, the U.S. government, Dow Chemical and Monsanto refused to admit any such connection because it would have meant paying out damages to victims and additional benefits to veterans. Only decades of litigation have managed to coerce the government and the chemical companies into settlements with Americans, Australians, South Koreans, New Zealanders, and Canadians. The Vietnamese, however, remain uncompensated for the carnage the chemicals caused.
Every day, insurance companies that maintain they have their policyholders’ wellbeing in mind and advertise their willingness to pay quickly and fully on claims made by those policyholders, deny benefits whenever possible for a variety of bogus or highly questionable reasons. Many companies have been sued and found liable for such conduct. Of course, none of this ever stopped an insurance company from collecting its premiums.
In the case of many dangerous prescription drugs, pharmaceutical companies have repeatedly refused to admit having known and withheld data concerning adverse reactions and side-effects that appeared during clinical trials. Manipulation and deletion of information has also been proven in many cases where approved drugs have had to be pulled from the market after injuring and killing hundreds or thousands of people.
So, is it any wonder that the City of New York, through its Health Commissioner, Dr. Thomas Frieden, has taken the rather questionable position that he would be “surprised” if anyone could conclusively link the death of someone like NYPD Detective James Zadroga to the hundreds of hours he spent breathing in the toxic air at ground Zero as he helped in the rescue and recovery efforts.

The Commissioner stated: “An autopsy can determine whether there was damage to the lungs and it can determine whether that damage might have been related to foreign bodies. But whether that was related to [the World Trade Center], I don’t think that would be easy to say definitively.”

Of course, there is a very good reason why the Frieden has taken this position. Any admission by the City or the NYPD would have far reaching effects since it would potentially force the re-classification of disability pensions and death benefits due to the injured police officers or their survivors.

It would also seriously affect the ongoing litigation against the City and other defendants that focuses on the negligent handling of the cleanup efforts that exposed thousands of city and private-sector workers and volunteers to the toxic hazards that were produced when the twin towers collapsed.

While the City often heaps additional benefits and posthumous promotions on police officers and firefighters killed in the “line of duty.” It has refused to acknowledge any such heroism on the part of the men and women who toiled without rest or regard for their own safety at the WTC site.

Speeches, plaques, and monuments are apparently one thing; conferring monetary benefits and admitting potential liability are something else.

Besides the anger and frustration expressed by Det. Zadroga’s parents, who now care for his orphaned 4-year-old daughter Tylerann, there is the medical and scientific evidence that 9/11 was not only a tragedy that killed almost 3,000 people instantly, but it was also an environmental catastrophe that has sickened countless people, had demonstrable effects on children born to mothers who lived near Ground Zero, and will probably kill or have long-term health effects on tens of thousands of people who were exposed to the toxic cloud that hovered over the site of the twin towers for months.

In an effort to demonstrate the causal connection between exposure to those toxins and the growing number of deaths, cancers, and other diseases, the Detectives’ Endowment Association (DEA) released the results of an autopsy done on Det. James Zadroga by the Ocean County, New Jersey, Medical Examiner.

That autopsy found that Det. Zadroga died as a direct result of respiratory failure brought on by the exposure to toxic substances and fine particles that he inhaled while working for some 470 hours at Ground Zero.

Det. Zadroga’s wife died of a stress-related heart attack only last year. His death earlier this year left his daughter an orphan.

The DEA wants Det. Zadroga’s death re-classified as having been in the “line of duty” so that his daughter will be able to receive a larger pension (100% instead of 75%) for at least seven additional years.

A number of other detectives appeared at the news conference. Each is suffering from serious respiratory problems or cancers that have left them totally disabled or terminally ill.

These NYPD officers are but a small number of the thousands of rescue workers and other responders who are claiming that the toxic cloud of airborne chemicals and solid particles that hung over the WTC site for weeks has killed and permanently injured many of them.

Shortly after Det, Zadroga’s death in January, the New York Daily News reported that 22 other relatively young men may also have died from respiratory-related illnesses caused or accelerated by their exposure to the same toxic environment while aiding in the post-9/11 cleanup.

Like Zadroga, most of the 22 men were only in their 30s and 40s. According to their families, they have died as a result of the deadly mixture of chemicals they were exposed to as they searched for survivors in the ruins of the World Trade Center or aided in the clean-up efforts in the days and weeks following the terrorist attack.

While the attack was immediately responsible for killing almost 3,000 innocent victims who were in and around the WTC, it now appears 9/11 has had, and will continue to have, far reaching effects on possibly thousands of other individuals who responded to the catastrophe that day and in the weeks that followed as part of the massive rescue, recovery, and cleanup efforts, without any regard to their own personal safety.

Many medical experts have already expressed serious concern that the first responders, rescue and recovery workers, volunteers of all kinds, and construction workers at the scene will inevitably suffer significant, if not fatal, health consequences as a result of their protracted exposure to all types of dust, debris, toxins, and other dangerous substances that polluted the WTC disaster site for several months following the collapse of the WTC buildings.

Among the additional 22 who have died are private employees, a sanitation worker, a correction officer, a utility worker, transit workers, firefighters, and police officers. Some, like Zadroga, suffered from black lung disease, while others died from cancers of the esophagus and pancreas.

David Knecht, a Lucent Technologies employee, worked for two months to re-establish communications at businesses near Ground Zero. At 35 he was diagnosed with lung cancer and died in March 2005, leaving behind two girls, now ages 3 and 4.

His wife Cathleen Knecht, 38, of Berkeley Heights, N.J. said “He was a nonsmoker and a swimmer.”

Knecht was one of many who have claimed to have been sickened with debilitating and potentially deadly ailments related to their presence at the WTC site. Thousands are sick and suffering from respiratory illnesses. Nearly 400 firefighters and paramedics have left the job because of career-ending illnesses that followed their work at Ground Zero.

David Worry, the attorney for approximately 7,300 Ground Zero workers says that rescue and clean-up workers were not properly protected for the dangerous job they had to perform. “This was a toxic waste site. People should have been walking around in moon suits.”

He anticipates there will be many more deaths and illnesses from worker’s exposure to deadly waste at Ground Zero. It is estimated that as many as 50,000 people worked at the site in the months after 9/11.

Worry’s firm has filed a class-action lawsuit, which is pending in United States District Court in Manhattan. The suit alleges that government officials and construction contractors negligently exposed workers to dangerous levels of toxins at the cleanup site.

The attorneys for the City deny any direct medical link between exposure to debris and the respiratory illnesses and cancers. Some doctors treating Ground Zero workers are also skeptical because cancers resulting from toxic exposure can take up to 15 to 20 years to develop.

They are disturbed, however, by the substantial number of young and otherwise healthy people who have died or become ill following similar exposure to the same environmental conditions.

“It’s still too early to say if WTC responders are at increased risk for cancer,” said Dr. Robin Herbert, director of the World Trade Center Health Effects Treatment Program at Mount Sinai School of Medicine. “But we remain very concerned.”

Another death involved Bob Shore, a city correction officer, who worked at the makeshift morgue at Ground Zero for at least two weeks, wearing only a paper mask. At the end of his first day handling body parts, Shore climbed into the shower fully dressed and cried for two hours.

Shore, a 53-year-old father of two died last August from pancreatic cancer. His doctor attributes his disease, which caused the once 300-pound bodybuilder to waste away to 110 pounds and to have his gallbladder, spleen, and pancreas removed, to his work at Ground Zero.

Shore’s widow, like many families of 9/11 recovery and rescue workers, says she now faces the impossibility of paying the medical bills, as much $200,000 for all her husband’s treatments.

Nevertheless, Michelle Shore remembers her husband’s selfless contribution to the recovery efforts: “He never regretted doing it,” she said “He was my hero, the city’s hero.”

Among the 7,300 plaintiffs in the class-action are several cancer cases including at least eleven for what is normally a rare, and often deadly, form of brain cancer. Three of the victims have already died and many of the others are seriously ill or dying. In all, 41 deaths are now alleged to have been caused by toxic exposure.

The police union and the attorney representing the plaintiffs in the class-action have pointed to police officers, firemen, a Red Cross worker, an EMS technician, an EPA employee, a construction worker, and other responders as examples of what appears to be an alarming (and growing) number of brain cancer victims.

In addition to these concerns was, and still is, the impact on babies of mothers who were pregnant when the attacks occurred and who lived within two miles of the World Trade Center.

As we reported only last month, the Columbia Center for Children’s Environmental Health (CCCEH) at the Columbia University Mailman School of Public Health has been conducting an ongoing study called the World Trade Center Pregnancy Study. Other institutions, organizations, and independent researchers have also studied the actual and potential future effects the massive amounts of toxins that were released as a result of the fine particles of pulverized building materials and the fires that incinerated the debris thereby releasing any number of cancer-causing chemicals into the air. (http://www.mailman.hs.columbia.edu/ccceh/research/wtc_pregnancy.html)

A number of articles were published between August 2003 and late 2004 that documented the fact that babies born to mothers who were pregnant when the attacks occurred and who were in or near the collapsing towers or who lived in close proximity to the site were smaller and had lower birth weights.

On August 5, 2003, the Associated Press reported that:

“Exposed pregnant women in the study faced double the risk of delivering babies who were up to about a half-pound smaller than babies born to non-exposed women.

The size differences among babies born to women exposed to dirt and soot from the attacks suggest a condition called intrauterine growth restriction, or IUGR, which has been linked with exposure to air pollution.

Previous research also has found that babies affected by IUGR may be at increased risk for heart disease, hypertension and other health problems in adulthood, said Dr. Philip Landrigan, chairman of Mount Sinai School of Medicine’s community and preventive medicine department, and one of the researchers.

While duration of the exposure was relatively short, ’the intensity of exposure to soot and dust was extraordinarily high,’ Landrigan said.

The study appears in Wednesday’s Journal of the American Medical Association.” http://www.cbsnews.com/stories/2003/08/05/health/main566807.shtml

The CCCEH study has published extensive amounts of information on the subject including the following:

“The destruction of the World Trade Center (WTC) on September 11, 2001 was an unprecedented environmental disaster, with enduring effects on the physical and psychological well-being of a nation. In lower Manhattan, the event released large amounts of dust and toxic pollutants into the air, including fine particulate matter derived from the burning of materials during the explosion and fires, construction debris, and asbestos. These exposures are known to be especially toxic to the vulnerable populations of pregnant women and their unborn infants, and have been linked to reduced fetal growth and subsequent neurodevelopmental problems. Widespread psychological distress could also affect birth outcomes and subsequent child functioning.

The Center’s study, launched in December 2001, is assessing the effects of prenatal exposure to contaminants released by the WTC destruction on gestational age, birth size, respiratory health, and neurocognitive development in 300 women who had term pregnancies. Thus far, study results show that babies born to women who were pregnant on 9/11 and lived near the WTC in the weeks after 9/11 were born lighter and shorter than were babies born to women living further away. Previous research shows that even small reductions in birth weight may lead to learning and behavioral problems.

The Center’s WTC Pregnancy Study is the only one of its kind to compare women with known exposure levels living and working close to the WTC site to a control group living and working further away from the site. The study is also unique in that pregnant women were enrolled prior to delivery, thereby eliminating participation bias that could arise from already knowing the outcome of their pregnancy.

Preliminary Findings

Results on birth size from the World Trade Center Study were published recently in Environmental Health Perspectives, a peer-reviewed journal (please click here to read the EHP paper):

Babies born to women who were living within 2 miles of the WTC in the month following 9/11/01 were on average 5 ounces lighter than babies born to women who lived further away.
Babies born to women who were living near the WTC in the month following 9/11 were on average 1/3 of an inch shorter at birth than babies born to women living further away.
All women were full term, however; women in their first 13 weeks of pregnancy on 9/11 (regardless of their distance from the WTC) had a shorter pregnancy by an average of 3.6 days compared to women who were in a later stage of pregnancy on 9/11. Babies born to mothers with shorter pregnancies had smaller head circumference than other babies.
Findings of decreased birth weight and length among full term infants of mothers who resided within 2 miles of the WTC site are potentially important for subsequent health and development. Lower birth weight, even within the normal range (>2500 g), is associated with increased fetal mortality, neonatal mortality, and infant mortality, subsequent poorer health, delayed physical and cognitive development, and increased susceptibility to stress in adulthood.”

In March, The New York Post ran an “EXCLUSIVE” by Susan Edelman that did an excellent job of bringing the public up to date on the progress and most recent findings of the CCCEH study.

In that article, interviews with investigators and the director of CCCEH, Dr. Frederica Perera, revealed that, as feared, genetic damage to the children being studied has been greater than in the case of other city children.

In fact, a considerable number of the children (about 50%) have DNA profiles with “significant levels of combustion-related toxins” (NY Post).

These findings are a sign of genetic damage and present the possibility of developmental damage and an increased risk of cancer although no such conclusions have been made at this point.

In light of this mountain of medical, scientific, and circumstantial evidence it is difficult to understand how the City can deny any causal connection between 9/11 and deaths like Det. Zadroga’s. Difficult to understand only until the money involved is considered, that is.

Regardless of whether some degree of liability is found on the part of the City of New York or any governmental agency, there seems to be little doubt that the number of victims of 9/11 will continue to climb for years or decades to come and that the full extent of the injuries and deaths caused to those who lived, worked, responded to, or were born near Ground Zero may never be known. The Zadroga autopsy may have supplied the first hard evidence of the connection despite what Commissioner Frieden says since his opinion appears to be driven more by economics than by medicine and science.


Bagolie Friedman Injury Lawyers

Friday, April 14, 2006

Treating Doctors vs. Defense Expert, Who Wins?

Very often in New Jersey workers' comp, the job will send an injured worker to one of their so called "independent" expert doctors. Usually, this is done when the insurance company disagrees with the treating doctor and wants to cut off treatment. When treatment and benefits are wrongfully terminated, it needs to be fought in Court and then it becomes a battle of the doctors.

There is hope for New Jersey's injured workers as their treating doctor will be given more weight than the insurance company's hired gun.

Pursuant to case law established in New Jersey, any conflict of opinion between
medical experts, generally greater weight is given to the opinion of the
treating physician. See Muews v. Union Bldg. & 'Contr. Cop., 45 N.J. Super.
89 (App. Div. 1957). Generally the physician treating the patient is in a
better position to express an opinion as to the cause and effect than one
making an examination in order to give expert testimony. Celeste v.
Progressive Silk Finishing Co., 72 N.J. Super. 233 (App. Div. 1962). Where
medical testimony is in conflict, greater weight ordinarily will given to
the testimony of the treating physician. Albelit v. General Motors Corp.,
46 N.J. Super. 475 (App. Div. 1957).

If you or a loved one has a work related injury, contact Bagolie Friedman Injury Lawyers now for a free and confidential consultation now.

Bausch & Lomb Urges Removal Of ReNu Contact Lens Solution

Apr 14, 2006 | Nishad Majmudar | www.democratandchronicle.com
Bausch & Lomb Inc. has asked all U.S. retailers to remove ReNu with MoistureLoc contact lens solution from their shelves.

"We find ourselves in a position where the safety of one of our products is in question," Chief Executive Ronald Zarrella wrote in a letter to consumers.

In the letter, which will appear today and Sunday in newspapers across the country, Zarrella said testing by the company and the Food and Drug Administration has so far not found a definitive link between the solution and reported case of a rare but threatening eye infection.

But he added, "Bausch & Lomb's first priority is the health and safety of consumers. If there is a problem with our product, we'll find it and we'll fix it. If there's not, when we come back, you'll be able to know with absolute certainty that we've taken every possible step to ensure your safety."

The company is recommending that consumers switch to another contact lens solution until an investigation into 109 U.S. cases of Fusarium keratitis is complete.

B&L said in a statement that it would offer product refunds.

The company had suspended U.S. sales of ReNu with MoistureLoc earlier this week because a disproportionately large number of the eye infections studied by public health authorities involved contact lens wearers who used a B&L lens cleaner made in the company's Greenville, S.C., plant.

B&L stock has fallen about 20 percent since Monday, but it rose slightly Thursday, finishing at $46.17, up 56 cents. But other ripple effects are now being felt.

Though no safety issues have arisen in Europe, two retail chains in Scandinavia, where B&L continues to ship ReNu with MoistureLoc, advised customers to change to a different brand until U.S. authorities have pinpointed the cause of the infections in the United States.

The chains were Synsam, which operates about 300 stores in Sweden, Finland and Norway, and Specsavers Blic Optik, which has about 40 stores in Sweden.

"Until this has been investigated in the U.S.A., the suspicion still remains," said Synsam's chief executive, Gunnar Harbom. "And for us, the suspicion is enough."

Several national retail chains, including Kmart, Sears, Walgreens, CVS, Rite Aid and Wal-Mart, had already pulled the product.

If you or a loved one experiences eye problems, contact Bagolie Friedman Injury Lawyers for a free and confidential consultation now.

Bausch & Lomb Urges Removal of ReNu Contact Lens Solution

Apr 14, 2006 | Nishad Majmudar | www.democratandchronicle.com
Bausch & Lomb Inc. has asked all U.S. retailers to remove ReNu with MoistureLoc contact lens solution from their shelves.

"We find ourselves in a position where the safety of one of our products is in question," Chief Executive Ronald Zarrella wrote in a letter to consumers.

In the letter, which will appear today and Sunday in newspapers across the country, Zarrella said testing by the company and the Food and Drug Administration has so far not found a definitive link between the solution and reported case of a rare but threatening eye infection.

But he added, "Bausch & Lomb's first priority is the health and safety of consumers. If there is a problem with our product, we'll find it and we'll fix it. If there's not, when we come back, you'll be able to know with absolute certainty that we've taken every possible step to ensure your safety."

The company is recommending that consumers switch to another contact lens solution until an investigation into 109 U.S. cases of Fusarium keratitis is complete.

B&L said in a statement that it would offer product refunds.

The company had suspended U.S. sales of ReNu with MoistureLoc earlier this week because a disproportionately large number of the eye infections studied by public health authorities involved contact lens wearers who used a B&L lens cleaner made in the company's Greenville, S.C., plant.

B&L stock has fallen about 20 percent since Monday, but it rose slightly Thursday, finishing at $46.17, up 56 cents. But other ripple effects are now being felt.

Though no safety issues have arisen in Europe, two retail chains in Scandinavia, where B&L continues to ship ReNu with MoistureLoc, advised customers to change to a different brand until U.S. authorities have pinpointed the cause of the infections in the United States.

The chains were Synsam, which operates about 300 stores in Sweden, Finland and Norway, and Specsavers Blic Optik, which has about 40 stores in Sweden.

"Until this has been investigated in the U.S.A., the suspicion still remains," said Synsam's chief executive, Gunnar Harbom. "And for us, the suspicion is enough."

Several national retail chains, including Kmart, Sears, Walgreens, CVS, Rite Aid and Wal-Mart, had already pulled the product.

If you or a loved one experiences eye problems, contact Bagolie Friedman Injury Lawyers for a free and confidential consultation now.

FOSAMAX ®, AREDIA ®, ZOMETA ® and ACTONEL ® Linked to Bone Death of the Jaw

FOSAMAX ®, AREDIA ®, ZOMETA ® and ACTONEL ® Bone Death of the Jaw
FOSAMAX ®, AREDIA ®, ZOMETA ® and ACTONEL ® are bisphosphonate medication used for bone loss. It's usage has been linked to the catastrophic condition known as "Dead Jaw" , also known as ONJ - Osteonecrosis of the Jaw or necrosis of the jaw or other bones.

If you or a loved one have taken any of these drugs for osteoporosis,cancer or multiple myeloma & you have experienced complications, contact Bagolie Friedman Injury Lawyers now for a free and confidential consultation.

In the U.S. Package Insert for both Aredia and Zometa, the following information on osteonecrosis had previously been added to the Adverse Reactions section under Post-Marketing Experience.

"Cases of osteonecrosis (primarily involving the jaws) have been reported in patients treated with bisphosphonates. The majority of the reported cases are in cancer patients attendant to a dental procedure. Osteonecrosis of the jaw has multiple well documented risk factors including a diagnosis of cancer, concomitant therapies (e.g., chemotherapy, radiotherapy, corticosteroids) and co-morbid conditions (e.g., anemia, coagulopathies, infection, pre-existing oral disease). Although causality cannot be determined, it is prudent to avoid dental surgery as recovery may be prolonged."

If you have been injured by Fosamax®, Actonel ®, Aredia®, or Zometa®, contact Bagolie Friedman Injury Lawyers now for a free and confidential consultation. Call toll free at 1-866-333-3529 or email at info@bagoliefriedman.com

Merck Sued Over Fosamax Health Risks

Merck Sued Over Fosamax Health Risks
From Bloomberg News
April 11, 2006


Merck & Co., which faces more than 9,000 lawsuits over its Vioxx painkiller, misrepresented the safety of its osteoporosis drug Fosamax by withholding warnings that it could kill jawbone tissue, according to a lawsuit filed Monday.

Linda Secrest, 59, sued Merck, accusing it of failing to warn doctors and patients that Fosamax could hamper blood flow to the jaw. Secrest, who began taking the drug in 2000, says she was diagnosed with jawbone tissue death in 2005. The condition is irreversible.

Merck should be ordered to change the Fosamax prescribing information given to doctors and pay the cost of medical monitoring for users, Secrest says.

The complaint, in federal court in Fort Myers, Fla., seeks to represent more than 10 million Fosamax users. It is the second of about 200 suits that Secrest's attorney said he planned to file.

Merck spokesman Chris Loder said claims of jawbone tissue death caused by Fosamax were "exceedingly rare." A warning notice was added to the drug's label in July 2005 at the Food and Drug Administration's request, he said.

Fosamax and Fosamax Plus D together are the most-prescribed medicine for osteoporosis in post-menopausal women.

If you or a loved one suffers from bone problems, contact Bagolie Friedman Injury Lawyers for a free and confidential consultation now

Merck Sued Over Fosamax Health Risks

Merck Sued Over Fosamax Health Risks
From Bloomberg News
April 11, 2006


Merck & Co., which faces more than 9,000 lawsuits over its Vioxx painkiller, misrepresented the safety of its osteoporosis drug Fosamax by withholding warnings that it could kill jawbone tissue, according to a lawsuit filed Monday.

Linda Secrest, 59, sued Merck, accusing it of failing to warn doctors and patients that Fosamax could hamper blood flow to the jaw. Secrest, who began taking the drug in 2000, says she was diagnosed with jawbone tissue death in 2005. The condition is irreversible.

Merck should be ordered to change the Fosamax prescribing information given to doctors and pay the cost of medical monitoring for users, Secrest says.

The complaint, in federal court in Fort Myers, Fla., seeks to represent more than 10 million Fosamax users. It is the second of about 200 suits that Secrest's attorney said he planned to file.

Merck spokesman Chris Loder said claims of jawbone tissue death caused by Fosamax were "exceedingly rare." A warning notice was added to the drug's label in July 2005 at the Food and Drug Administration's request, he said.

Fosamax and Fosamax Plus D together are the most-prescribed medicine for osteoporosis in post-menopausal women.

Tuesday, April 11, 2006

Bausch & Lomb Suspends Contect Lens Solution Shipment

Officials Probe Eye Infection Outbreak
Apr 10, 2006 ANDREW BRIDGES AP

Bausch & Lomb voluntarily suspended shipment of a contact lens solution after federal health officials linked it Monday to a fungal eye infection that can cause temporary blindness.The

Centers for Disease Control and Prevention is investigating 109 reports of Fusarium keratitis infection in patients in 17 states since June 2005.Federal and state health officials have interviewed just 30 of those patients. However, of the 28 who wore soft contact lens, however, 26 reported using Bausch & Lomb's ReNu brand contact lens solution or a generic type of solution also made by the Rochester, N.Y., company.Bausch & Lomb said it would temporarily suspend shipments of ReNu with MoistureLoc made at its Greenville, S.C., plant."The CDC data released today are both troubling and perplexing, as there is an apparent disproportionate representation of U.S.-manufactured ReNu with MoistureLoc in the underlying data.

The source of these infections has not been determined," company chairman and chief executive officer Ronald Zarrella said. Five of the 26 patients also reported using other types of solutions in addition to ReNu, Bausch & Lomb said. And nine said they wore their lenses overnight, which is known to increase the risk of infection, the CDC said.Dr. Daniel Schultz, director of the Food and Drug Administration's Center for Devices and Radiological Health, said it was too early to determine if Bausch & Lomb's solution was the cause of the infections. Both the FDA and CDC are investigating a growing number of reports of infection by the fungus. An estimated 30 million Americans wear soft contact lenses."We are relatively early in this investigation. It may be we will find this particular product does not have an association. We may find a strong association," Schultz told reporters.

The fungus is commonly found in plant material and soil in tropical and subtropical areas. Singapore health officials noticed an increase in reports of infection in January and discovered 39 cases involving contact lens users from 2005 to February of this year. Cases have also been reported in Malaysia and Hong Kong.In February, Bausch & Lomb halted sales of its ReNu contact lens solution in Singapore and Hong Kong.Without treatment, which can last two to three months, the infection can scar the cornea and blind its victims. Eight U.S. patients have required cornea transplants.Soft contact users with eye redness or pain, tearing, increased light sensitivity, blurred vision or discharge should stop wearing contacts and contact a doctor immediately, said Dr. Malvina Eydelman, director of the FDA's Division of Ophthalmic and Ear, Nose and Throat Devices. The FDA also advises users to wash their hands well with soap and water before handling lenses and to follow cleaning and storage guidelines.In addition, contact lens wearers who use ReNu with MoistureLoc should do so with caution, the FDA said.